Oncology

Latest News

The investigators found that patients with SCLC and cachexia were more likely to have problems with treatment. | Image credit: appledesign - stock.adobe.com

Cachexia Worsens Prognosis in Older Patients With Advanced SCLC

July 9th 2025

Older patients with small cell lung cancer and significant weight loss were more likely to experience dose interruptions than patients with cachexia.

Insurance gaps | Image Credit: iQoncept-stock.adobe.com

Insurance Gaps Threaten Cancer Treatment Success

By Maggie L. Shaw

July 7th 2025

Analyzed by birth cohort, the authors found each successive birth cohort had a 7.7% decline in SCLC rates. | Image credit: shidlovski

Decline in SCLC Incidence Expected to Accelerate Through 2050

By Jared Kaltwasser

June 29th 2025

While elevated NLR previously served as a marker of aggressive disease and poor prognosis in SCLC, its prognostic relevance appears to diminish in the context of immunotherapy-based treatment regimens. | Image credit: Crystal light - stock.adobe.com

Challenging the Prognostic Role of NLR in SCLC in the Era of Immunotherapy

By Kimberly Rath, PharmD

June 27th 2025

Gender rights | Image Credit: © Nadzeya-stock.adobe.com

Culture Key to Data Collection of Sexual Orientation and Gender Identity in Cancer Care

By Maggie L. Shaw

June 23rd 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

Continuing Medical Education

View All

July 10th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

July 10th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

December 20th 2016

Will the FDA Replicate the Oncology Center of Excellence?

Surabhi Dangi-Garimella, PhD

The 21st Century Cures Act mandates the creation of "one or more" intercenter institutes at the FDA. But is such a massive reorganization feasible within the FDA?

December 19th 2016

First NGS-Based Companion Diagnostic Approved With Rucaparib for Advanced Ovarian Cancer

AJMC Staff

The FDA has provided accelerated approval for rupacarib along with the first next-generation sequencing—based companion diagnostic test, for the treatment of women with advanced ovarian cancer.

December 19th 2016

Surabhi Dangi-Garimella, PhD

Here's a look at some of the most popular articles published in Evidence-Based Oncologyâ„¢ in 2016.

December 19th 2016

Will a Payer-Provider Collaboration Guarantee OCM Success?

Surabhi Dangi-Garimella, PhD

At the Payer Exchange Summit V, in Tyson’s Corner, Virginia, oncologists and payers came together to discuss the role of collaboration and data sharing for the successful implementation of the Oncology Care Model (OCM).

December 18th 2016

Dr Joseph Alvarnas Discusses Clinical Risk in Value-Based Cancer Care

The new era of data informatics tools can help providers and payers understand the tiers of risk that determine the economics of care delivery, which is crucial to value-based cancer treatment, according to Joseph Alvarnas, MD, of the City of Hope and editor-in-chief of Evidence-Based Oncology

December 16th 2016

CMS Decision to Abandon Medicare Part B Demo Greeted With Sighs of Relief

Christina Mattina

After widespread criticism from healthcare providers, drug companies, and lawmakers, CMS has announced that it will not go forward with its proposed Medicare Part B payment program. The experimental reimbursement model was intended to reduce outpatient drug spending, but oncologists worried it would have unfairly slashed their Part B payments.

December 16th 2016

This Week in Managed Care: December 16, 2016

This week, the top stories in managed care include President Barack Obama signing the 21st Century Cures Act into law, findings from the CDC that opioid abuse has reduced life expectancy for Americans, and CVS announced a new program to lower costs for patients with diabetes.

December 16th 2016

Craig Sager Loses His Fight Against AML

Surabhi Dangi-Garimella, PhD Mary Caffrey

Craig Sager, a sideline reporter for CNN and Turner Sports, has died a little over 2 and a half years after being diagnosed with acute myeloid leukemia (AML).

December 15th 2016

Strategies for OCM Implementation at the COA Payer Summit

Surabhi Dangi-Garimella, PhD

At the Community Oncology Alliance (COA) Payer Exchange Summit V, panelists provided insights for successful implementation of payment models in oncology clinics.

December 15th 2016

How Can Practices Seek Success With Oncology Payment Reform?

Surabhi Dangi-Garimella, PhD

Bruce Gould, MD, president and medical director, Northwest Georgia Oncology Center, and president of the Community Oncology Alliance, presented an overview of how cancer care has improved over the years and what the current challenges are.

December 15th 2016

Jonathan Hirsch: How Syapse Uses Health IT to Implement Precision Medicine

Implementing precision medicine is a complex undertaking that cannot be accomplished without the use of health IT tools, according to Jonathan Hirsch, founder and president of Syapse. He identified the 4 key functions of healthcare IT that allow Syapse to expand access to precision medicine.

December 15th 2016

Second Scalp Cooling Device to Prevent Chemotherapy-Induced Alopecia Seeks FDA Approval

Surabhi Dangi-Garimella, PhD

Paxman is seeking approval for using its scalp cooling device as an intervention to prevent chemotherapy-induced alopecia (CIA) in women undergoing chemotherapy treatment for breast cancer.

December 14th 2016

NIH-Funded Survey Reports Decline in Vaping and Use of Hookahs, Cigarettes by Teens

Surabhi Dangi-Garimella, PhD

A survey funded by the National Institutes of Health (NIH)’s National Institute on Drug Abuse has found that vaping, cigarette smoking, and use of hookahs among adolescents has declined over the past year.

December 14th 2016

Preventing Chemotherapy-Associated Alopecia: A Case for Palliation?

Surabhi Dangi-Garimella, PhD

Chemotherapy-associated alopecia, which drastically changes how a person looks and feels, can significantly impact the patient’s quality of life, over and above the physical exhaustion associated with their treatment. Raising awareness among providers, patients, and their caregivers can help.

December 13th 2016

Palliative Care for Patients With Advanced Illness: A Changing Policy Landscape

Sharon Pearce

A lag in policy changes has resulted in significant variation across palliative care programs for treating advanced illnesses. A recent shift in policy has, however, allowed small-scale testing of community-based palliative care delivery and some innovations in other delivery systems.

December 13th 2016

FDA Reaffirms Bladder Cancer Risk With Use of Pioglitazone

Surabhi Dangi-Garimella, PhD

The FDA has released an updated safety announcement following a fresh review of data on the type 2 diabetes treatment pioglitazon to confirm that the drug may increase a person’s likelihood of developing bladder cancer.

December 13th 2016

Step Therapy Cost-Effective for Psychological Distress in Patients With Cancer

AJMC Staff

A study published in the Journal of Clinical Oncology has found that step therapy can be cost-effective in patients with cancer who are under psychological duress.

December 13th 2016

Barry Russo on Quality Measures Data and Value Frameworks

Barry Russo, CEO of The Center for Cancer & Blood Disorders, said that his practice continues to collect quality and claims data from a number of sources, even though it isn’t easy. Russo also said that payers are not particularly interested in participating in a value framework, instead choosing to focus on the oncology care model (OCM).

December 12th 2016

Social Ties Significantly Impact Survival of Patients With Breast Cancer

Surabhi Dangi-Garimella, PhD

An exhaustive study conducted by researchers at the Kaiser Permanente Division of Research has found that a woman’s social network can significantly affect her chances of survival following breast cancer.

December 12th 2016

Achieving Value Through Palliative Care

Allison Silvers, MBA Stacie Sinclair, MPP Diane E. Meier, MD, FACP

Palliative care is an underutilized and powerful resource in the drive towards value. In the current article, we review published evidence and highlight how Medicare Advantage plans, accountable care organizations, and oncology practices can benefit from concurrent palliative care under value-based payments.

December 9th 2016

Smoking Cessation Programs Need a Boost Under Medicaid Expansion

Surabhi Dangi-Garimella, PhD

The CDC's Morbidity and Mortality Weekly Report recommends that Medicaid expansion states should direct more attention to smoking cessation programs to improve access and raise awareness about these programs among beneficiaries and providers.

December 9th 2016

Welcome to the Future: Telemedicine and Value-Based Payment

Michael D. Fratkin, MD Stephen G. Franey, MBA

By using telemedicine and relocating the center of care to where a person lives, we have an opportunity to address more unmet demand for palliative care, while giving more control to the seriously ill to meet their stated needs.

December 9th 2016

This Week in Managed Care: December 9, 2016

This week, the top stories in managed care included poll results that show growing numbers of Republicans want the Affordable Care Act scaled back instead of repealed, Jardiance received a new indication for patients with type 2 diabetes, and CareMore reported care coordination gaps for seniors.

December 8th 2016

Researchers Develop Model to Predict Chemotherapy Success in Aggressive Breast Cancer

Christina Mattina

At the 2016 San Antonio Breast Cancer Symposium, researchers announced the creation of a model to identify patients with triple negative breast cancer who are most likely to respond to chemotherapy.

December 8th 2016

Integrating Palliative Care Into Outpatient Oncology: A Case Study

Karen Mulvihill, DNP, APRN, FNP-BC, ACHPN

This article examines the integration of palliative care in a community cancer center-an example of how one program integrated palliative care.

December 7th 2016

ASCO Makes Recommendations to Reduce Cardiac Risk in Survivors of Adult-Onset Cancers

Surabhi Dangi-Garimella, PhD

A panel of 21 expert clinicians from the field conducted a systematic review of meta-analyses randomized clinical trials, observational studies, and clinical experience, to develop recommendations that have been published in the Journal of Clinical Oncology.

December 6th 2016

CAR T-Cells of Defined Composition Effective in Ibrutinib-Refractory CLL

Surabhi Dangi-Garimella, PhD

In high-risk patients with chronic lymphocytic leukemia (CLL), CD19 chimeric antigen receptor (CAR) T-cells of defined composition can be administered with an acceptable early toxicity.

December 5th 2016

Innovative Approach to Precision Trial Design: NCI-MATCH and Beat AML

Surabhi Dangi-Garimella, PhD

Representatives from the Beat acute myeloid leukemia (AML) and National Cancer Institute-Molecular Analysis for Therapy Choice (NCI-MATCH), which incorporate genomic profiling to assign patients to different treatment arms, provided an insight on trial design and a progress report.

December 5th 2016

Dr Robert Carlson Discusses Future of Immuno-Oncology, Importance of Patient Advocacy

Immuno-oncology will be an important part of cancer care in the future, but probably not the only part, predicted Robert W. Carlson, MD, CEO of the National Comprehensive Cancer Network. He also explained how patient advocacy and an enduring healthcare system are essential to the advancement of cancer care.

December 5th 2016

RESONATE-2 Continues to Impress With Single-Agent Ibrutinib for CLL/SLL at 29 Months

Surabhi Dangi-Garimella, PhD

Older patients diagnosed with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) continue to present a favorable response to single-agent ibrutinib, at a follow-up of 29 months, in phase 3 of the RESONATE-2 trial.

...

86 87 88 89 90 91 92 93 94

...

186 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions